Determination of two COX-2 inhibitors in serum and synovial fluid of patients with inflammatory arthritis by ultra performance liquid chromatography-inductively coupled plasma mass spectroscopy and quadrupole time-of-flight mass spectrometry.
Τίτλος | Determination of two COX-2 inhibitors in serum and synovial fluid of patients with inflammatory arthritis by ultra performance liquid chromatography-inductively coupled plasma mass spectroscopy and quadrupole time-of-flight mass spectrometry. |
Publication Type | Journal Article |
Year of Publication | 2009 |
Authors | Gika, H. G., Theodoridou A., Michopoulos F., Theodoridis G., Diza E., Settas L., Nikolaidis P., Smith C., & Wilson I. D. |
Journal | J Pharm Biomed Anal |
Volume | 49 |
Issue | 3 |
Pagination | 579-86 |
Date Published | 2009 Apr 5 |
ISSN | 1873-264X |
Λέξεις κλειδιά | Adult, Aged, Arthritis, Chromatography, High Pressure Liquid, Cyclooxygenase 2 Inhibitors, Female, Humans, Male, Mass Spectrometry, Middle Aged, Pyrazoles, Pyridines, Reference Standards, Spectrometry, Mass, Electrospray Ionization, Sulfonamides, Sulfones, Synovial Fluid, Young Adult |
Abstract | The determination of two sulphur-containing drugs, the COX-2 inhibitors celecoxib and etoricoxib, in the serum and synovial fluid of inflammatory arthritis patients, is described using a sensitive ultra performance liquid chromatography-inductively coupled plasma mass spectroscopy (UPLC/ICPMS) method. Confirmation of the identity of the analytes in the samples was also performed by electrospray quadruple time-of-flight mass spectrometry in positive electrospray ionisation mode. The two COX-2 inhibitors were extracted from serum and synovial fluid following dilution with acetate buffer (pH 5) and liquid-liquid extraction (LLE) into ethyl acetate. Extracted samples were then analysed using UPLC/ICPMS with sulphur-specific detection. The limit of detection by UPLC/ICPMS was 0.45 ng/ml of sulphur in both serum and synovial fluid. The UPLC/ICPMS method was applied to the analysis of samples from patients receiving either 200 mg/day of celecoxib (2x 100 mg), 90 mg/day etoricoxib or placebo. The range of concentrations detected in the samples for the two drugs was from 0.3 to 3.3 microg/ml. |
DOI | 10.1016/j.jpba.2008.12.006 |
Alternate Journal | J Pharm Biomed Anal |
PubMed ID | 19155154 |